

HUMAN ANTIBODIES & HYBRIDOMAS

7-9 November 2012, Buena Vista Palace Hotel, Orlando, Florida, USA

FINAL ORAL PROGRAMME HAH 2012

SCIENTIFIC ADVISORY COMMITTEE

Programme Chairman: Professor Mark Glassy (*IMSA, San Diego, USA*)

Mirek Gorny (*New York University School of Medicine, New York, USA*)

Zdenka L. Jonak (*GlaxoSmithKline, USA*)

Henry Lowman (*CytomX Therapeutics Inc., South San Francisco, California, USA*)

J. Donald Capra (*OMRF, USA*)

Roberto Burioni (*Universita Vita-Salute San Raffaele, Milan, Italy*)

Kathy Potter (*Southampton University, UK*)

Jim Larrick (*Panorama Research Inc., USA*)

Alois Lang (*GeNeuro SA, Geneva, Switzerland*)

David P. Humphreys (*UCB-Celltech, Slough, UK*)

Markus Enzelberger (*MorphoSys AG, Martinsried, Germany*)

Eszter Nagy (*Arsanis GmbH, Vienna, Austria*)

Sachdev Sidhu (*University of Toronto, Canada*)

John Haurum (*f-star, Cambridge, UK*)

Paul Kerr (*Fusion Antibodies, Northern Ireland, UK*)

Yan Wu (*Kadmon Pharmaceuticals LLC, New York, USA*)

Bob Kelley (*Genentech Inc., South San Francisco, USA*)

Torben P. Frandsen (*Symphogen A/S, Lyngby, Denmark*)

David Naor (*The Hebrew University, Jerusalem, Israel*)

Alex von Gabain (*Intercell AG, Vienna, Austria*)

Jody Berry (*Becton Dickinson, La Jolla, California, USA*)

Manuel Baca (*MedImmune Inc., Gaithersburg, Maryland, USA*)

Jean-Luc Teillaud (*INSERM/Cordeliers Research Centre, Paris, France*)

Dale Ludwig (*ImClone Inc., New York, USA*)



09.10-09.15

Welcome & Opening Remarks

Mark C. Glassy

(*IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA*)

**SESSION 1:
OPENING PLENARY**

Moderator:

Mark C. Glassy

(*IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA*)

09.15-09.45

'Novel applications of antibody therapeutics in cardiovascular medicine'

James W. Larrick (*Panorama Research Institute, Sunnyvale, California, USA*)

09.45-10.15

'Generation of human antibodies using somatic hypermutation in vitro'

David King (*AnaptysBio Inc., San Diego, California, USA*)

10.15-10.45

'A modular antibody technology to create bispecific mAb²'

John Haurum (*f-Star, Cambridge, UK*)

10.45-11.05

Coffee Break

**SESSION 2:
CANCER I**

Moderator: David Naor (*The Hebrew University, Jerusalem, Israel*)

11.05-11.30

'The potential of natural B cells in a tumor microenvironment'

Mark C. Glassy

(*IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA*)

11.30-11.55

'Long-lasting anti-tumor protection through adaptive immune response induced by anti-CD20 mAb treatment'

Jean-Luc Teillaud (*INSERM / Cordeliers Research Center, Paris, France*)

11.55-12.20

'Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells'

Serge Krysov, Samantha Dias, Alex Paterson, C. Ian Mockridge, Kathleen N. Potter, Kelly-Ann Smith, Margaret Ashton-Key, Freda Stevenson and Graham Packham (*University of Southampton, Southampton, UK*)

12.20-12.45

'Antibody-drug conjugates (ADCs): The next wave of antibody-based anti-cancer agents?'

John Lambert (*Immunogen Inc., Waltham, Massachusetts, USA*)

12.45-14.00

Lunch Break

**SESSION 3:
AUTOIMMUNITY**

Moderator: James W. Larrick

(*Panorama Research Institute, Sunnyvale, California, USA*)

14.00-14.30

'Hyaluronic acid target receptors (CD44 and RHAMM) involved in treatment of type 1 diabetes'

David Naor (*The Hebrew University, Jerusalem, Israel*)

14.30-14.50

'Preliminary safety and pharmacokinetics of GNBAC1, a humanized monoclonal antibody antagonist of the multiple sclerosis retrovirus envelope protein'

Alois B. Lang (*GeNeuro SA, Geneva, Switzerland*)

14.50-15.10

'Therapeutic antibodies to treat inflammatory diseases'

Steven Coats (*MedImmune Inc., Gaithersburg, Maryland, USA*)

15.10-15.30

'Citruinated epitope as target for novel therapeutic antibodies in RA'

Jos Raats (*ModiQuest Research, Nijmegen, The Netherlands*)

15.30-16.00

Tea Break

**SESSION 4:
INFECTIOUS DISEASES I**

Moderator: Alois B. Lang (*GeNeuro SA, Geneva, Switzerland*)

16.00-16.30

'Discovery & development of human B-cell derived therapeutic monoclonal antibody candidates for indications of infectious disease'

Kristine Swiderek (*Theraclone Sciences, Seattle, Washington, USA*)

16.30-17.00

'Discovery of unique human monoclonal antibodies that counteract staphylococcal virulence factors'

Ester Nagy (*Arsanis GmbH, Vienna, Austria*)

17.00-17.20

'Cross-neutralizing activity of human anti-HIV-1 monoclonal antibodies do not correlate with the percentage of mutations in their variable fragments'

Miroslaw K. Gorny, Constance Williams, Barbara Volsky, Xiao-Hong Wang, Liuzhe Li, Michael S. Seaman and Susan Zolla-Pazner (*New York University, New York, USA*)

17.20-17.40

'Immune complex vaccines to elicit antibodies against HIV-1 neutralizing epitopes'

Catarina E. Hioe, Rajnish Kumar, Maria Luisa Visciano, Hualin Li and Michael Tuen (*New York University School of Medicine, New York, USA*)

17.40-18.00

'MB-2003: an antibody based immunoprotectant for Ebola virus'

Larry Zeitlin (*MAPP Biopharmaceuticals Inc., San Diego, California, USA*)

18.00-19.00

HAH 2012 Welcome Drinks Reception



SESSION 5: MOLECULAR BIOLOGY

Moderator: David Humphreys (*UCB Pharma, Slough, Berkshire, UK*)

09.00-09.30

'Engineering mouse immune loci to generate novel antibody-like molecules'

Lynn Macdonald (*Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA*)

09.30-09.50

'Ylanthia – A novel library concept for the generation of antibody drug candidates'

Stefanie Urlinger (*Morphosys AG, Martinsried, Germany*)

09.50-10.10

'Genetic immunization, an alternative for generating therapeutic antibodies'

Thomas W. Lynch (*Aldevron, Madison, Wisconsin, USA*)

10.10-10.30

'The OMT antibody platform: Fully human antibodies from transgenic rats'

Roland Buelow (*OMT Inc., Palo Alto, California, USA*)

10.30-11.00

Coffee Break

SESSION 6: INFECTIOUS DISEASES II

Moderator: Miroslaw K. Gorny (*New York University, New York, USA*)

11.00-11.30

'Improved antibody therapies for the treatment of *Clostridium difficile* infection'

David Humphreys (*UCB Pharma, Slough, Berkshire, UK*)

11.30-11.50

'An effective approach for the generation and characterization of neutralizing monoclonal antibodies to viral targets'

Nancy Chan, Lena Kikuchi, Adam Feire, Peter LeMotte and Chonghui Zhang (*Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA*)

11.50-12.10

'An endogenous human antibody against a conserved M2 epitope confers full protection against influenza A strains'

Roger Beerli (*Intercell AG, Schlieren, Switzerland*)

12.10-12.30

'Immunogenic mechanisms driving norovirus G11.4 antigenic variation'

Lisa Lindesmith (*University of North Carolina, Chapel Hill, North Carolina, USA*)

12.30-12.50

'Development of catalytic human antibody light chains (antigenases) showing suppression of rabies virus infection'

Taizo Uda, Akira Nishizono and Emi Hifumi (*Oita University, Oita-shi, Japan*)

12.50-14.00

Lunch Break

SESSION 7: CANCER II

Moderator: Jean-Luc Teillaud

(*INSERM / Cordeliers Research Center, Paris, France*)

14.00-14.30

'Development of monoclonal antibody based cancer therapeutics targeting B7-H3'

Paul Moore (*Macrogenics Inc., Rockville, Maryland, USA*)

14.30-14.50

'Recruiting T cells to destroy tumors: a tetravalent bispecific anti-CD19 x anti-CD3 TandAb designed for the treatment of hematological malignancies'

Eugene Zhukovsky (*Affimed Therapeutics AG, Heidelberg, Germany*)

14.50-15.10

'Human antibody light chains (antigenases) showing cytotoxicity against cancer cells'

Emi Hifumi and Taizo Uda (*Oita University, Oita-shi, Japan*)

15.10-15.40

Tea Break

SESSION 8A: SPECIAL PRESENTATION

Moderator: Mark C. Glassy

(*IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA*)

15.40-16.10

'Virtual microscopy: The next paradigm shift in pathology and how it applies to immunohistochemistry stains'

Eric F. Glassy

(*Affiliated Pathologists Medical Group, Torrance, California, USA*)

SESSION 8B: SPECIAL PRESENTATION

Moderator: Mark C. Glassy

(*IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA*)

16.10-16.40

'Monoclonal antibody patents: Evolving law & strategies'

Andrew Serafini (*Fenwick & West LLP, Seattle, Washington, USA*)

Free Evening for Delegates

**SESSION 9:
MAB PRODUCTION & DSP ISSUES**

Moderator: David Humphreys (*UCB Pharma, Slough, Berkshire, UK*)

09.00-09.30

'Investigating the use of chromatin structure modifying elements to increase antibody expression and clone stability in CHO-K1 cells'

Kerry Tyson (*UCB Pharma, Slough, Berkshire, UK*)

09.30-09.50

'Development of recombinant antibody mixtures for targeting of multiple epitopes'

Torben P. Frandsen (*Symphogen A/S, Lyngby, Denmark*)

09.50-10.10

'Developing the next generation designer cell lines as a customized approach for optimized therapeutic protein production'

Pierre-Alain Girod (*Selexis, Geneva, Switzerland*)

10.10-10.30

'Selections with cells and membranes using a yeast-based IgG discovery platform enables isolation and successful optimization of human antibodies against integral membrane proteins'

Jerry Thomas (*Adimab LLC, Lebanon, New Hampshire, USA*)

10.30-11.00

'High throughput generation of antibodies to novel, modified and difficult targets'

Stefan Dubel (*Technische Universitat Braunschweig, Braunschweig, Germany*)

11.00-11.15

Coffee Break

**SESSION 10:
PRE-CLINICAL**

Moderator: Torben P. Frandsen (*Symphogen A/S, Lyngby, Denmark*)

11.15-11.45

'CASE STUDY: Moving Pritumumab from a hybridoma to a CHO expression system'

Gregory T. Bleck (*Catalent Biologics, Middleton, Wisconsin, USA*)

11.45-12.05

'Comparability and characterization of fully human IgM antibodies'

Michael Rudolf (*Kenta Biotech, Zurich, Switzerland*)

12.05-12.25

'Humanization and cell development for Clinical Studies: A case study'

Richard Buick (*Fusion Antibodies Ltd, Belfast, Northern Ireland*)

12.25-12.45

'Preclinical efficacy and safety of Probody™ therapeutics'

Henry B. Lowman

(*CytomX Therapeutics Inc., South San Francisco, California, USA*)

12.45-13.05

'Augmented clearance of botulinum neurotoxin using a bispecific 'heteropolymer' antibody specific for complement receptor type 1 (CR1) on RBC's'

Sharad P. Adekar, Ahmed Syed Ubaid, Andrew T. Segan, Ramadevudu Puligedda, Margaret A. Lindorfer, Cindy Chen, Rodney Bermudez, Sarang Puranik, Lance L. Simpson, Ronald P. Taylor and Scott K. Dessain (*Immunome Inc., Wynnewood, Pennsylvania, USA*)

13.05-14.00

Lunch Break

**SESSION 11:
LATE-BREAKER PRESENTATIONS**

Moderator: Mark C. Glassy

(*IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA*)

14.00-14.20

'Manufacture of recombinant IgM-antibodies – A case study'

H. Katinger, K. Fauland, R. Weik, M. Barut, S. Peljhan, A. Strancar and M. Zorz (*Polymun Scientific GmbH, Klosterneuberg, Austria*)

14.20-14.40

'A novel antigen specific immunoglobulin expressing cell lineage in immune animals distinct from classical B cell populations'

Jody Berry (*BD Biosciences, La Jolla, California, USA*)

14.40-15.00

'Human primary B lymphocytes for the rapid high throughput discovery of native therapeutic monoclonal antibodies'

Majid Mehtali (*Vivalis, Saint-Herblain, Nantes, France*)

15.00-15.20

'Synthetic human antibodies targeting staphylococcal enterotoxin B (SEB) for prophylaxis and treatment of toxic shock syndrome'

Gang Chen, Hatice Karauzum, Laura Abaandou, Mahta Mahmoudieh, Atefeh R. Boroun, Sergey Shulenin, V. Sathya Devi, Eric Stavale, Kelly L. Warfield, Larry Zeitlin, Chad J. Roy, M. Javad Aman and Sachdev S. Sidhu (*University of Toronto, Toronto, Canada*)

15.20-15.40

'Biological features of human catalytic antibody light chains showing suppressive effect on influenza virus infection'

Naoko Fujimoto, Emi Hifumi and Taizo Uda (*Oita University, Oita-shi, Japan*)

**SESSION 12:
CLOSING PLENARY**

Moderator: Mark C. Glassy

(*IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA*)

15.40-16.10

'Human antibodies – where are we at and where are we going? – including summary of HAH 2012 conference'

J. Donald Capra (*OMRF, Oklahoma City, Oklahoma, USA*)

16.10-16.15

Closing Remarks & Departure

* This final programme is correct at the time of printing. However the organisers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme.